Back to Search
MARK KIPNES, MD
Endocrinology, Diabetes & Metabolism Physician
NPI: 1376501965Individual
Specialties, Licenses & Credentials
Endocrinology, Diabetes & Metabolism PhysicianPrimary
Internal Medicine — Endocrinology, Diabetes & Metabolism
Code: 207RE0101X
G7539(TX)
Research & Publications (19)
Dapagliflozin: an emerging treatment option in type 2 diabetes.
PMID 19243283·Expert Opin Investig Drugs·2009
6-review
Control of postprandial plasma glucose by an oral insulin product (HIM2) in patients with type 2 diabetes.
PMID 12547873·Diabetes Care·2003
3-trial
Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.
PMID 11448655·Am J Med·2001
3-trial
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy.
PMID 19125778·Diabetes Obes Metab·2009
4-observational
Evaluation of various doses of recombinant human thyrotropin in patients with multinodular goiters.
PMID 18996810·Endocr Pract·2008
3-trial
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
PMID 17593236·Diabetes Obes Metab·2007
2-rct
Effects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapy.
PMID 16784180·Diab Vasc Dis Res·2006
3-trial
Immunomodulation in type 1 diabetes by NBI-6024, an altered peptide ligand of the insulin B epitope.
PMID 16398702·Scand J Immunol·2006
3-trial
Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
PMID 16912128·J Clin Endocrinol Metab·2006
4-observational
Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes.
PMID 17022853·Curr Med Res Opin·2006
2-rct
Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome.
PMID 17130190·Diabetes Care·2006
2-rct
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.
PMID 17130196·Diabetes Care·2006
2-rct
Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial.
PMID 15110130·Clin Ther·2004
3-trial
The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study.
PMID 15537471·Curr Med Res Opin·2004
8-other
Striant SR: a novel, effective and convenient testosterone therapy for male hypogonadism.
PMID 15605676·Int J Clin Pract·2004
6-review
New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men.
PMID 15292312·J Clin Endocrinol Metab·2004
3-trial
Short-term pharmacokinetic comparison of a novel testosterone buccal system and a testosterone gel in testosterone deficient men.
PMID 15140340·Curr Med Res Opin·2004
3-trial
Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension.
PMID 15081441·Am J Cardiol·2004
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 5107 MEDICAL DRIVE
SAN ANTONIO, TX 78229 - Phone
- (210) 614-8612
Quick Facts
- NPI
- 1376501965
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 19
Are you this provider?
Claim Your Profile